This mechanism is not drug- or tumor-type specific, because it is elicited also by the natural product tanshinone IIA, another HIF-1α inhibitor that impairs EMT and alleviates the hypoxia-induced resistance to doxorubicin in breast cancer cells [147]. The gene discussed is HIF1A; the disease is breast carcinoma.